Grufity logoGrufity logo
ScreenerStocksFundsSectorsWatchlists
CGEM

Cullinan Management, Inc.

CGEM

8.12USD-0.32 (-3.79%)Market Closed
Watchlist

Market Summary

USD8.12-0.32
Market Closed
-3.79%

CGEM Stock Price

View Fullscreen

CGEM RSI Chart

CGEM Valuation

Market Cap

347.2M

Price/Earnings (Trailing)

-2.23

Price/Sales (Trailing)

4.16

EV/EBITDA

-1.78

Price/Free Cashflow

-2.44

CGEM Price/Sales (Trailing)

CGEM Profitability

EBT Margin

116.94%

Return on Equity

13.28%

Return on Assets

12.53%

Free Cashflow Yield

-40.96%

CGEM Fundamentals

CGEM Revenue

Revenue Y/Y

56.33%

CGEM Earnings

Earnings (TTM)

-155.9M

Earnings Y/Y

-57.97%

Earnings Q/Q

-21.63%

Price Action

Last 7 days

-5.7%

Last 30 days

-17.1%

Last 90 days

-23.4%

Trailing 12 Months

-31.2%

How does CGEM drawdown profile look like?

CGEM Financial Health

Current Ratio

15.25

CGEM Investor Care

Buy Backs (1Y)

6.52%

Diluted EPS (TTM)

-3.73

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs
Net sales
YearQ1Q2Q3Q4
20230000
202241.1M63.2M85.3M107.4M
202100018.9M

Latest Insider Trading transactions for CGEM

Filter Transactions
Datesorted ascendingNameBuy/Sell$ ValueAvg. Price# SharesTitle
Jun 30, 2023
trigilio jeffrey
acquired
21,247
9.08
2,340
chief financial officer
Jun 28, 2023
ahmed nadim
sold
-8,652
11.4
-759
president and ceo
Jun 20, 2023
jones jeffrey alan
sold
-5,007
12.94
-387
chief medical officer
Jun 20, 2023
sumer jacquelyn l
sold
-3,765
12.94
-291
chief legal officer
Jun 20, 2023
michaelson jennifer
sold
-3,079
12.94
-238
chief development officer
Jun 20, 2023
trigilio jeffrey
sold
-5,163
12.94
-399
chief financial officer
Jun 12, 2023
michaelson jennifer
sold
-2,307
13.11
-176
chief development officer
Jun 12, 2023
trigilio jeffrey
sold
-4,182
13.11
-319
chief financial officer
Jun 07, 2023
michaelson jennifer
sold
-1,240
12.4
-100
chief development officer
Jun 07, 2023
michaelson jennifer
acquired
430
4.3
100
chief development officer

1–10 of 50

Which funds bought or sold CGEM recently?

View All Details
Datesorted ascendingFund NameType% Chg$ Change$ Held% Portfolio
Nov 24, 2023
DEUTSCHE BANK AG\
reduced
-44.33
-47,449
41,784
-%
Nov 21, 2023
COMERICA BANK
new
-
1,105
1,105
-%
Nov 17, 2023
JACOBS LEVY EQUITY MANAGEMENT, INC
sold off
-100
-901,096
-
-%
Nov 15, 2023
JANE STREET GROUP, LLC
reduced
-69.17
-429,424
150,357
-%
Nov 15, 2023
MORGAN STANLEY
reduced
-12.82
-933,021
2,564,920
-%
Nov 15, 2023
Rubric Capital Management LP
unchanged
-
-1,072,050
5,673,710
0.21%
Nov 15, 2023
Annandale Capital, LLC
added
20.00
1,000
109,000
0.03%
Nov 15, 2023
PUBLIC EMPLOYEES RETIREMENT SYSTEM OF OHIO
sold off
-100
-53,000
-
-%
Nov 15, 2023
MANUFACTURERS LIFE INSURANCE COMPANY, THE
unchanged
-
-18,283
96,763
-%
Nov 15, 2023
Baker Avenue Asset Management, LP
unchanged
-
-82.00
434
-%

1–10 of 46

Latest Funds Activity

Are funds buying CGEM calls or puts?
Calls
Puts
No. of funds holding Calls - Puts
Net Call Options
No. of funds that own CGEM
No. of Funds

Schedule 13G FIlings of Cullinan Management, Inc.

Date FiledName of FilerPercent of ClassNo. of SharesForm Type
Sep 07, 2023
blackrock inc.
4.8%
2,036,651
SC 13G/A
Feb 15, 2023
jovan-embiricos morana
3.4%
1,577,440
SC 13G/A
Feb 14, 2023
biotechnology value fund l p
8.9%
4,058,854
SC 13G/A
Feb 13, 2023
chi advisors llc
7.25%
3,317,544
SC 13G/A
Feb 09, 2023
vanguard group inc
6.15%
2,812,965
SC 13G/A
Feb 03, 2023
blackrock inc.
5.5%
2,506,215
SC 13G
Feb 14, 2022
biotechnology value fund l p
6.4%
2,790,018
SC 13G/A
Feb 11, 2022
foresite capital fund v, l.p.
2.6%
1,143,006
SC 13G/A
Feb 11, 2022
chi advisors llc
5.67%
2,476,720
SC 13G
Feb 09, 2022
vanguard group inc
5.42%
2,366,808
SC 13G

Recent SEC filings of Cullinan Management, Inc.

View All Filings
Date Filed Form Type Document
Nov 08, 2023
8-K
Current Report
Nov 08, 2023
10-Q
Quarterly Report
Sep 07, 2023
SC 13G/A
Major Ownership Report

Peers (Alternatives to Cullinan Management, Inc.)

View All Peers In Detail
NameMkt Capsorted ascendingRevenuePrice %, 1MReturns, 1YP/EP/SRev 1-YrInc 1-Yr
LARGE-CAP
31.4B
-
4.92% 426363.59%
-3.6K
218.4K
- -102.45%
30.7B
10.7B
11.84% -53.56%
-8.86
2.88
-53.67% -129.46%
22.0B
1.7B
4.71% -20.32%
-43.06
12.74
79.37% 56.87%
17.7B
2.3B
23.54% -7.88%
120.62
7.68
15.05% 75.21%
12.4B
3.6B
1.56% -32.86%
29.22
3.44
8.35% -51.49%
MID-CAP
7.5B
272.9M
38.55% 34.32%
-12.3
27.31
141.38% 4.43%
5.6B
-
16.25% 246.63%
-9.66
48.33
54.84% -12.96%
3.5B
631.9M
-10.80% 43.56%
-23.57
5.55
23.54% 31.53%
3.3B
223.4M
11.07% -7.88%
-16.25
14.68
- -26.24%
2.6B
240.7M
-11.66% -25.68%
-12.44
10.6
-1.03% -16.59%
SMALL-CAP
1.5B
348.4M
7.85% -14.88%
24.07
4.29
81.69% -7.29%
662.5M
1.0B
-19.01% -66.75%
-1.21
0.63
-43.15% 58.48%
100.5M
6.4M
-2.56% -78.77%
-0.61
15.6
-44.11% 50.48%
42.3M
-
410.00% -4.38%
-0.65
-
- -29.23%
26.3M
-
17.86% 4717.52%
-0.55
-
- -13.74%

Cullinan Management, Inc. News

Latest updates
InvestorIdeas.com30 Aug 201806:22 pm5 years ago

Financials for Cullinan Management, Inc.

Income Statement (Last 12 Months)
Income Statement (Quarterly)
Description(%) Q/Q2023Q32023Q22023Q12022Q42022Q32022Q22022Q12021Q42021Q32021Q22021Q1
Revenue------173,566,00086,783,000---18,943,000
Operating Expenses19.1%44,803,00037,605,00062,756,00032,608,00029,766,00037,106,00032,657,00034,347,00018,375,00016,604,00017,571,000
  S&GA Expenses7.5%10,982,00010,214,00010,660,00011,287,00010,086,00010,695,0008,121,00013,469,0005,695,0004,826,0005,156,000
  R&D Expenses23.5%33,821,00027,391,00052,096,00021,321,00019,680,00026,411,00024,536,00020,878,00012,680,00011,778,00012,415,000
EBITDA Margin---1.171.410.741.20-5.16-1.58-0.40--
Income Taxes-----1,858,000-2,523,00066,070,000-19,568,000----
Earnings Before Taxes-21.6%-39,183,000-32,214,000-58,141,000-28,946,000-27,413,000240,135,000-32,460,000-34,206,000-18,259,000-16,439,0001,419,000
EBT Margin---1.171.410.741.20-5.16-1.59-0.40--
Net Income-21.6%-39,183,000-32,214,000-58,141,000-26,385,000-24,804,000174,898,000-12,892,000-32,857,000-17,350,000-16,439,0001,419,000
Net Income Margin---0.601.040.520.33-4.10-3.46-0.81--0.33
Free Cashflow----51,156,000-25,865,000-54,436,666--21,908,000-15,171,000-10,551,000-16,196,000-1,515,000
Balance Sheet
(In Millions)
Balance Sheet
(In Millions)
(*) denotes actual numbers (not divided by Millions)
Description(%) Q/Q2023Q32023Q22023Q12022Q42022Q32022Q22022Q12021Q42021Q32021Q22021Q12020Q4
Assets-5.2%495522515561617667437437453464480215
  Current Assets-4.3%477498399474582623322297329344447212
    Cash Equivalents-54.3%65.0014212215624335476.0060.0088.00124294168
  Net PPE-7.9%1.001.001.001.001.000.000.000.000.000.000.000.00
Liabilities15.5%26.0022.0029.0026.0031.0063.0018.0012.008.006.0010.0014.00
  Current Liabilities19.2%23.0020.0026.0022.0027.0062.0017.0012.008.006.0010.0014.00
Shareholder's Equity-6.2%469500486535586605419425445459470200
  Retained Earnings-28.4%-177-137-105-47.69-20.914.00-171-158-126-109-93.41-93.34
  Additional Paid-In Capital1.2%647639593585611604593585570565560292
Shares Outstanding0.1%43.0043.0039.0046.0046.0045.0044.0044.0043.0043.0042.0030.00
Minority Interest------0.001.000.002.003.003.001.00
Cashflow (Last 12 Months)
(In Millions)
Cashflow (Quarterly)
Description(%) Q/Q2023Q32023Q22023Q12022Q42022Q32022Q22022Q12021Q42021Q32021Q22021Q12020Q42020Q32020Q22020Q1
Cashflow From Operations-10.1%-34,141,000-31,006,000-50,997,000-24,983,000-54,353,000-25,420,000-21,908,000-15,171,000-10,551,000-16,196,000-1,515,000-9,436,000-9,071,000-6,250,000-5,015,000
  Share Based Compensation-2.3%7,740,0007,920,0007,259,0007,513,0005,271,0008,608,0006,565,00012,145,0004,557,0004,165,0003,508,000----
Cashflow From Investing-454.7%-42,958,00012,110,00015,184,000-28,610,000-57,978,000300,852,00034,711,000-15,862,000-25,593,000-154,594,000-137,726,00011,440,000-1,941,00011,971,000-26,890,000
Cashflow From Financing-99.7%112,00038,602,0001,789,000-32,912,0001,425,0002,013,0003,541,0002,702,000579,000923,000264,580,000124,897,0001,206,000-14,037,000
  Buy Backs------------6,359,000--213,000

CGEM Income Statement

2023-09-30
CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE INCOME (LOSS) - USD ($)
shares in Thousands, $ in Thousands
3 Months Ended9 Months Ended
Sep. 30, 2023
Sep. 30, 2022
Sep. 30, 2023
Sep. 30, 2022
Income Statement [Abstract]    
Income (loss) from operations$ (45,243)$ (29,766)$ (145,604)$ 177,256
Operating expenses:    
Research and development33,82119,680113,30870,627
General and administrative10,98210,08631,85628,902
Total operating expenses44,80329,766145,16499,529
Gain on sale of Cullinan Pearl000276,785
Impairment of long-lived assets(440)0(440)0
Other income (expense):    
Interest income5,8802,35315,7103,247
Other income (expense), net1800356(241)
Net income (loss) before income taxes(39,183)(27,413)(129,538)180,262
Income tax expense (benefit)0(2,523)043,979
Net income (loss)(39,183)(24,890)(129,538)136,283
Net loss attributable to noncontrolling interests0(86)(179)(1,713)
Net income (loss) attributable to common stockholders of Cullinan(39,183)(24,804)(129,359)137,996
Comprehensive income (loss):    
Net income (loss)(39,183)(24,890)(129,538)136,283
Unrealized gain on investments574(296)1,550(3,091)
Comprehensive income (loss)(38,609)(25,186)(127,988)133,192
Comprehensive loss attributable to noncontrolling interests0(86)(179)(1,713)
Comprehensive income (loss) attributable to Cullinan$ (38,609)$ (25,100)$ (127,809)$ 134,905
Net income (loss) per share attributable to common stockholders of Cullinan:    
Basic$ (0.91)$ (0.54)$ (3.15)$ 3.07
Diluted$ (0.91)$ (0.54)$ (3.15)$ 2.96
Weighted-average shares used in computing net income (loss) per share attributable to common stockholders of Cullinan    
Weighted-average common stock outstanding - basic42,73445,61141,13044,966
Diluted42,73445,61141,13046,580

CGEM Balance Sheet

2023-09-30
CONSOLIDATED BALANCE SHEETS - USD ($)
$ in Thousands
Sep. 30, 2023
Dec. 31, 2022
Current assets:  
Cash and cash equivalents$ 64,847$ 156,152
Short-term investments401,583311,140
Prepaid expenses and other current assets10,2827,180
Total current assets476,712474,472
Property and equipment, net1,0661,174
Operating lease right-of-use assets2,9254,130
Other assets459459
Long-term investments13,54580,882
Total assets494,707561,117
Current liabilities:  
Accounts payable9512,660
Accrued expenses and other current liabilities20,94614,135
Income tax payable04,282
Operating lease liabilities, current1,5471,421
Total current liabilities23,44422,498
Long-term liabilities:  
Operating lease liabilities, net of current portion2,4463,590
Total liabilities25,89026,088
Commitments and contingencies (Note 11)
Stockholders' equity:  
Preferred stock, $0.0001 par value, 10,000,000 shares authorized as of September 30, 2023 and December 31, 2022; 647,500 and no shares issued and outstanding as of September 30, 2023 and December 31, 2022, respectively00
Common stock, $0.0001 par value, 150,000,000 shares authorized as of September 30, 2023 and December 31, 2022; 42,760,644 and 45,796,449 shares issued and outstanding as of September 30, 2023 and December 31, 2022, respectively45
Additional paid-in capital646,918585,320
Accumulated other comprehensive loss(1,051)(2,601)
Accumulated deficit(177,054)(47,695)
Total Cullinan stockholders' equity468,817535,029
Noncontrolling interests00
Total stockholders' equity468,817535,029
Total liabilities and stockholders' equity$ 494,707$ 561,117
CGEM
Cullinan Oncology, Inc. a clinical-stage biopharmaceutical company, focuses on developing a pipeline of targeted oncology and immuno-oncology therapies for cancer patients in the United States. The company's lead candidate is the CLN-081, an orally bioavailable small-molecule that is in a Phase IIb dose escalation for treating patients with non-small cell lung cancer. Its products also include CLN-049, a humanized bispecific antibody that is in Phase I clinical trial for the treatment of acute myeloid leukemia or myelodysplastic syndrome; CLN-619, a monoclonal antibody that is in Phase I clinical trial for the treatment of solid tumors; and CLN-418, a human bispecific antibody that is in Phase 1 clinical trial for the treatment of solid tumors. In addition, the company's preclinical product includes CLN-617, a fusion protein for the treatment of solid tumors; and CLN-978, a T cell engaging antibody for the treatment relapsed/refractory B-cell non-Hodgkin lymphoma. The company has collaboration agreements with Cullinan Pearl Corp. to develop, manufacture, and commercialize CLN-081 and products containing CLN-081; and Adimab, LLC to discover and/or optimize antibodies. Cullinan Oncology, Inc. was incorporated in 2016 and is headquartered in Cambridge, Massachusetts.
 CEO
 WEBSITEwww.cullinanoncology.com
 EMPLOYEES62

Cullinan Management, Inc. Frequently Asked Questions


What is the ticker symbol for Cullinan Management, Inc.? What does CGEM stand for in stocks?

CGEM is the stock ticker symbol of Cullinan Management, Inc.. Every public company that trades on a stock exchange gets a ticker symbol.

What is the market capital of Cullinan Management, Inc. (CGEM)?

As of Wed Dec 06 2023, market cap of Cullinan Management, Inc. is 347.22 Million. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

What is the fair value of CGEM stock?

You can check CGEM's fair value in chart. The fair value of Cullinan Management, Inc. is provided for various growth and macro-economic scenarios from very pessimiatic to very optimistic assumptions. These fair values are estimates from Grufity's Fair Value model based on company's past performance. However, past performance of Cullinan Management, Inc. is no guarantee of future performance. These fairvalue estimates should only be used as one of the inputs in your stock analysis. We provide model's historical fair value estimates for CGEM so that you know how good or bad the model has been in the past so you can discard it if needed. There are others that provide fair values of stocks such as wallmine, finbox, gurufocus and finviz. Most provide point in time estimates. We provide a history of our models fair value estimates so that you can get a sense of it's usefulness. Otherwise this data point is of little use.

Is Cullinan Management, Inc. a good stock to buy?

The fair value guage provides a quick view whether CGEM is over valued or under valued. Whether Cullinan Management, Inc. is cheap or expensive depends on the assumptions which impact Cullinan Management, Inc.'s fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for CGEM.

What is Cullinan Management, Inc.'s Price to Earnings (PE) and Price to sales (PS) ratio?

As of Wed Dec 06 2023, CGEM's PE ratio (Price to Earnings) is -2.23 and Price to Sales (PS) ratio is 4.16. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. CGEM PE ratio will change depending on the future growth rate expectations of investors.